Russian top diplomat urges West to avoid disrupting ceasefire in SyriaRussian Politics & Diplomacy January 17, 13:48
Lavrov hopes Trump’s administration won’t preach to RussiaRussian Politics & Diplomacy January 17, 13:37
Lavrov dismisses allegations of cyberattacks on Western countries as 'cooked-up evidence'Russian Politics & Diplomacy January 17, 13:24
Lavrov slams EU policy towards Russia as 'shortsighted'Russian Politics & Diplomacy January 17, 13:17
Lavrov believes US wanted to use IS, Jabhat al-Nusra to overthrow AssadRussian Politics & Diplomacy January 17, 13:10
ECHR orders Russia to pay compensation for Dima Yakovlev lawWorld January 17, 13:04
Press review: EU's 'Russian hacker' hysteria and Le Pen's vows to recognize CrimeaPress Review January 17, 13:00
Top diplomat says strategic stability dialogue with US on Russia’s priority listRussian Politics & Diplomacy January 17, 12:27
Kremlin confirms US constantly put pressure on Russian diplomats during Obama's presidencyRussian Politics & Diplomacy January 17, 12:17
MOSCOW, April 14 (Itar-Tass) —— The Russian Skolkovo innovation centre’s resident company is developing innovative medicines against AIDS.
“These medicines use an absolutely new mechanism of action. Molecules affect structural protein that is critical for the HIV virus,” Quantum Pharmaceuticals Deputy Director Maxim Kholin said in an exclusive interview with Itar-Tass.
“The mechanism of action has its peculiarities and they allow us to expect our medicines to be less toxic for the human organism than many others now available. This is very important because the development of medicines against HIV is facing two problems: the virus is highly variable and medicines are toxic,” Kholin noted.
“We are continuing research and getting good results,” he added.
“Skolkovo has supported our project and helped us move forward considerably. It’s important to say that the substances have been developed using our own molecular modelling technology, one of the leading technologies in the world. We also actively use this technological platform for developing other antiviral medicines, new cancer medications and antibiotics. We work both on our own and in partnership with leading international research centres,” Kholin said.